학술논문
Relationship Between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients With Diabetes and Mild Heart Failure: Results From the CANDLE Trial
Document Type
Article
Author
Nakatani, Daisaku; Dohi, Tomoharu; Hikoso, Shungo; Tanaka, Atsushi; Nanasato, Mamoru; Shimizu, Wataru; Node, Koichi; Sakata, Yasushi; Ajioka, Masayoshi; Ako, Junya; Amano, Rie; Anzai, Toshihisa; Asai, Mitsutoshi; Dohi, Kaoru; Eguchi, Kazuo; Eshima, Kenichi; Fujiki, Shinya; Fujita, Masashi; Hikoso, Shungo; Hiramitsu, Shinya; Hoshide, Satoshi; Hoshino, Akihiko; Ikeda, Yuki; Ikehara, Yumi; Inomata, Takayuki; Inoue, Teruo; Ishii, Katsuhisa; Ishizaka, Nobukazu; Ito, Masaaki; Iwahashi, Noriaki; Iwakura, Katsuomi; Kadokami, Toshiaki; Kamiya, Haruo; Kanbara, Takahiro; Kanzaki, Yumiko; Kashimura, Ken; Kida, Keisuke; Kimura, Kazuo; Kishi, Satoru; Kitada, Shuichi; Kiyosue, Akihiro; Kodama, Kazuhisa; Kojima, Takayuki; Kondo, Takumi; Kubota, Yoshiaki; Kusunose, Kenya; Machii, Noritaka; Matsunaga, Kazuo; Matsuo, Yasuto; Matsuzawa, Yashushi; Mikami, Takeshi; Minamino, Toru; Nagai, Takahiro; Nagano, Yasuko; Nagumo, Masashi; Nakamura, Ikuko; Nakamura, Katsunori; Nakatani, Daisaku; Nanasato, Mamoru; Naruse, Hiriyuki; Nishino, Masami; Niwano, Shinichi; Oguri, Mitsutoshi; Ohte, Nobuyuki; Oikawa, Masayoshi; Okumura, Takahiro; Okumura, Masanori; Onishi, Katsuya; Ozaki, Yukio; Saito, Kan; Sakamoto, Tomohiro; Sakata, Yasushi; Sakuma, Masashi; Sekino, Hisakuni; Shiina, Kazuki; Shimabukuro, Michio; Shimizu, Wataru; Suzuki, Makoto; Suzuki, Kunihiro; Takahama, Hiroyuki; Takahashi, Naohiko; Takeishi, Yasuchika; Tamaki, Shunsuke; Tanaka, Akihiro; Tanimoto, Syuzo; Teragawa, Hiroki; Tobushi, Tomoyuki; Toita, Takafumi; Tokuda, Kotaro; Tomiyama, Hirofumi; Tsutsui, Hiroyuki; Uehara, Hiroki; Uematsu, Masaaki; Watada, Hirotaka; Yahagi, Kazuyuki; Yamada, Takahisa; Yamada, Hirotsugu; Yoshida, Tatsuya; Yoshihisa, Akiomi
Source
Journal of Cardiovascular Pharmacology; July 2023, Vol. 82 Issue: 1 p61-68, 8p
Subject
Language
ISSN
01602446; 15334023
Abstract
Supplemental Digital Content is Available in the Text.There were few clinical studies on the relationship between sodium glucose cotransporter 2 inhibitors (SGLT2i) and hematopoiesis in patients with diabetes (DM) and heart failure (HF) with consideration of systemic volume status. A total of 226 DM patients with HF enrolled in the CANDLE trial, a multicenter, prospective, randomized open-label blinded-endpoint trial, were studied. Estimated plasma volume status (ePVS) was calculated based on a weight- and hematocrit-based formula. At baseline, there was no significant difference in hematocrit and hemoglobin between the canagliflozin (n = 109) and glimepiride (n = 116) groups. Hematocrit and hemoglobin at 24 weeks, changes in hematocrit and hemoglobin difference (24 weeks-baseline), and hematocrit and hemoglobin ratio (24 weeks/baseline) were significantly higher in the canagliflozin than in the glimepiride group, respectively. There was no significant difference in ePVS at baseline and 24 weeks between the 2 groups. After adjustment for baseline parameters, canagliflozin correlated positively with changes in hematocrit and hemoglobin difference, and hematocrit and hemoglobin ratio by multivariate linear regression analyses. The difference in hematocrit and hemoglobin between the 2 groups became statistically significant at 3 and 6 months after randomization. There was no heterogeneity between canagliflozin and the characteristics of the patients for hematocrit and hemoglobin difference and ratio. A correlation of the changes in hematocrit and hemoglobin with cardiac and renal improvement was not observed. In conclusion, canagliflozin was associated with an increased hematocrit and hemoglobin in patients with diabetes and HF regardless of their volume status and characteristics.